Difference between revisions of "T-cell acute lymphoblastic leukemia"
m (Text replacement - "<span style="background:#EEEE00; padding:3px 6px 3px 6px; border-color:black; border-width:2px; border-style:solid;">Phase II</span>" to "style="background-color:#EEEE00"|Phase II") |
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
||
Line 30: | Line 30: | ||
===References=== | ===References=== | ||
− | # Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. [http://onlinelibrary.wiley.com/doi/10.1002/pbc.25470/abstract link to original article] [ | + | # Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. [http://onlinelibrary.wiley.com/doi/10.1002/pbc.25470/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25755211 PubMed] |
==Pediatric-like GRAALL induction {{#subobject:b90dc3|Regimen=1}}== | ==Pediatric-like GRAALL induction {{#subobject:b90dc3|Regimen=1}}== | ||
Line 51: | Line 51: | ||
===References=== | ===References=== | ||
<!-- Presented at the 56th Annual Meeting of the American Society of Hematology, San Francisco, CA, December 6-9, 2014. --> | <!-- Presented at the 56th Annual Meeting of the American Society of Hematology, San Francisco, CA, December 6-9, 2014. --> | ||
− | # Lepretre S, Touzart A, Vermeulin T, Picquenot JM, Tanguy-Schmidt A, Salles G, Lamy T, Béné MC, Raffoux E, Huguet F, Chevallier P, Bologna S, Bouabdallah R, Benichou J, Brière J, Moreau A, Tallon-Simon V, Seris S, Graux C, Asnafi V, Ifrah N, Macintyre E, Dombret H. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. J Clin Oncol. 2016 Feb 20;34(6):572-80. Epub 2015 Dec 7. [http://jco.ascopubs.org/content/34/6/572.full link to original article] [http://jco.ascopubs.org/content/suppl/2015/12/07/JCO.2015.61.5385.DC1/DS_2015.615385.pdf link to data supplement] '''contains protocol''' [ | + | # Lepretre S, Touzart A, Vermeulin T, Picquenot JM, Tanguy-Schmidt A, Salles G, Lamy T, Béné MC, Raffoux E, Huguet F, Chevallier P, Bologna S, Bouabdallah R, Benichou J, Brière J, Moreau A, Tallon-Simon V, Seris S, Graux C, Asnafi V, Ifrah N, Macintyre E, Dombret H. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. J Clin Oncol. 2016 Feb 20;34(6):572-80. Epub 2015 Dec 7. [http://jco.ascopubs.org/content/34/6/572.full link to original article] [http://jco.ascopubs.org/content/suppl/2015/12/07/JCO.2015.61.5385.DC1/DS_2015.615385.pdf link to data supplement] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26644537 PubMed] |
=Relapsed/Refractory= | =Relapsed/Refractory= | ||
Line 78: | Line 78: | ||
===References=== | ===References=== | ||
− | # DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007 Jun 15;109(12):5136-42. Epub 2007 Mar 7. [http://www.bloodjournal.org/content/109/12/5136.long link to original article] '''contains verified protocol''' [ | + | # DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007 Jun 15;109(12):5136-42. Epub 2007 Mar 7. [http://www.bloodjournal.org/content/109/12/5136.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17344466 PubMed] |
[[Category:Chemotherapy regimens]] | [[Category:Chemotherapy regimens]] | ||
[[Category:Malignant hematology regimens]] | [[Category:Malignant hematology regimens]] | ||
[[Category:Leukemia regimens]] | [[Category:Leukemia regimens]] |
Revision as of 03:10, 2 December 2016
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
5 regimens on this page
6 variants on this page
|
Note that many of the regimens used to treat this disease are generic to acute lymphoblastic leukemia; this page contains regimens that are specific to T-cell acute lymphoblastic leukemia (a.k.a. T-cell lymphoblastic lymphoma when primarily nodal-based).
Induction therapy
AALL0434 Induction
back to top |
Regimen
Study | Evidence |
Winter et al. 2015 | Phase II |
To be completed
References
- Winter SS, Dunsmore KP, Devidas M, Eisenberg N, Asselin BL, Wood BL, Leonard Rn MS, Murphy J, Gastier-Foster JM, Carroll AJ, Heerema NA, Loh ML, Raetz EA, Winick NJ, Carroll WL, Hunger SP. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015 Jul;62(7):1176-83. Epub 2015 Mar 8. link to original article PubMed
Pediatric-like GRAALL induction
back to top |
Regimen
Study | Evidence |
Lepretre et al. 2015 (GRAALL-LYSA LL03) | Phase II |
This regimen was meant for patients less than 60 years old (up to age 59). Regimen is as per the GRAALL-2003 Study with some minor differences, to be completed. High-risk patients with an HLA sibling-matched donor or a fully matched (10/10) unrelated donor who achieved CR1 were offered allogeneic stem cell transplant.
References
- Lepretre S, Touzart A, Vermeulin T, Picquenot JM, Tanguy-Schmidt A, Salles G, Lamy T, Béné MC, Raffoux E, Huguet F, Chevallier P, Bologna S, Bouabdallah R, Benichou J, Brière J, Moreau A, Tallon-Simon V, Seris S, Graux C, Asnafi V, Ifrah N, Macintyre E, Dombret H. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study. J Clin Oncol. 2016 Feb 20;34(6):572-80. Epub 2015 Dec 7. link to original article link to data supplement contains protocol PubMed
Relapsed/Refractory
Nelarabine (Arranon)
back to top |
Regimen
Study | Evidence |
DeAngelo et al. 2007 (CALGB 19801) | Phase II |
See paper for details about the schedule.
Chemotherapy
- Nelarabine (Arranon) 1.5 g/m2 IV over 2 hours once per day on days 1, 3, 5
21-day cycle for 3 to 4 cycles (or delayed for count recovery)
References
- DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, Gockerman JP, Mitchell BS, Appelbaum FR, Larson RA. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood. 2007 Jun 15;109(12):5136-42. Epub 2007 Mar 7. link to original article contains verified protocol PubMed